Yates v. Secretary of Health and Human Services

United States Court of Federal Claims·Decided November 12, 2020·No. 14-560·Published

Opinion

In the United States Court of Federal Claims No. 14-560V

(Originally filed under seal: October 13, 2020)

(Re-filed: November 12, 2020) 1

**************************

JEAN YATES Individually and as representative of the late ROBERT YATES,

National Childhood

Petitioner, Vaccine Injury Act, 42 U.S.C. §§300aa-1 to -34

v. (2012); Motion for review; Meningococcal

SECRETARY OF HEALTH conjugate (“Menactra”) AND HUMAN SERVICES, vaccine; Off-table claim;

Causation.

Respondent.

************************** Patricia Finn, Piermont, NY, for petitioner.

Voris E. Johnson, Senior Trial Attorney in the Torts Branch of the Civil Division, Department of Justice, Washington, DC, with whom were Joseph H. Hunt, Assistant Attorney General, trC. Salvatore D’Alessio, Acting Director, Catharine E. Reeves, Deputy Director, and Alexis B. Babcock, Assistant Director, for respondent.

OPINION

BRUGGINK, Judge.

This is a case brought under the National Childhood Vaccine Injury Act for compensation for injuries allegedly sustained after Robert Joseph

1 This opinion was held for fourteen days during which the parties were permitted to propose to chambers any appropriate redactions. The parties did not propose any redactions and thus we re-issue the decision without redactions. Rules of the United States Court of Federal Claims, App. B, Rule 18(b) (“Vaccine Rules”).

Yates received the meningococcal conjugate (“Menactra”) vaccine on July 27, 2012. Robert’s mother, Jean Yates (“petitioner”) filed a petition on behalf of her deceased son on June 30, 2014, alleging that the administration of the Menactra vaccine by Mount Kisco Medical Group caused Robert’s death.

Pending is petitioner’s motion for review of the Special Master’s decision of April 16, 2020, denying compensation. Yates v. Sec’y of Health & Human Servs., No. 14-560V, 2020 WL 2313691 (Fed. Cl. Spec. Mstr. Apr. 16, 2020). The motion is fully briefed, and the court finds that oral argument is unnecessary. Because the Special Master was not arbitrary or capricious and did not abuse her discretion in determining that petitioner had not demonstrated that the Menactra vaccine caused her son’s death, we deny the motion for review.

BACKGROUND

I. Factual History

The factual history of petitioner’s claim is not in dispute. 2 And although we summarize the facts and procedural history here, we adopt in full the excellent presentation by the Special Master in this difficult and complex case. Robert Joseph Yates was born on January 9, 1994. Pet.’s Ex. 1 at 9 (ECF No. 6-1) (Medical Records of Robert Yates). Robert had a history of autism and epilepsy but was otherwise healthy. Id. at 15. Robert attended a special needs program, and liked computers, trains, and magazines. Id. In 2011, Robert was treated for seizures, a fever, hematuria, 3 an upper respiratory infection, a contusion on his right foot, and possible strep throat. Id. at 9-32. On July 20, 2011, during Robert’s 17-year-old

2 Petitioner adopted the Special Master’s factual record set forth in the Special Master’s decision, and concurs it is consistent with the contemporaneous medical records proffered, and allegations in the petition. Pet.’s Mot. for Review at 3, 5 (ECF No. 98). 3 Hematuria is blood in the urine. On September 23, 2011 Robert was examined because a few drops of blood were noticed in Robert’s urine. On physical exam, Dr. Barsh noted Robert appeared healthy, showed no signs of illness, fever, and Robert was not indicating any pain, nor did he have signs of a renal stone. Pet.’s Ex. 1 at 28.

checkup, Robert’s cardiac exam revealed “regular rate and rhythm without murmur, rub or gallop.” Id. at 25. Dr. Elliot Barsh described Robert as a “well-developed, well-nourished boy, in no acute distress,” and that Robert was a “healthy 17-year old young man with autistic spectrum disorder.” Id.

The following year, Robert was treated for a persistent cough and earache, dermatitis and seizures, a deficiency in vitamin D, and possible pneumonia. Id. at 34-35, 37, 39. Early in 2012, on February 22nd, Robert had a neurologic appointment with Dr. Tania-Marie Sweeney who reviewed Robert’s medications. Id. at 41. Robert was taking 2500mg of Keppra in the morning, and 3000mg of Keppra in the afternoon to control seizures. His parents had also added another pill of Keppra to Robert’s evening dose following a recent seizure. Id.

Mr. Yates explained to Dr. Sweeney that usually he and Ms. Yates, could avoid taking Robert to the emergency room (“ER”) for seizures, but, on February 9, 2012, Robert had a seizure on the school bus, and so an ambulance was called. Id. at 40-41. After arriving at the emergency room, Mr. Yates recommended to the medical personnel that they give Robert clonazepam, which they did. Id. Robert was not given Keppra even though he was due to receive a dose. Id. On the way home from the ER, Robert had another seizure; so Mr. Yates gave Robert another 2mg of clonazepam and Robert seemed fine. Id. Robert saw his pediatrician the next day because the ER doctor said Robert may have pneumonia. Id. The pediatrician ruled out pneumonia after she examined Robert. Id. Robert’s February 22, 2020 examination concluded with Dr. Sweeney reviewing Robert’s medications with his parents and outlining a plan to continue his current medications, which involved Robert taking 1mg of clonazepam at night, 10 mg of Valium in the morning and evening, and vitamin D weekly. Id. Dr. Sweeney also indicated she did not want to increase Robert’s Keppra since his dosage was already high but instead wanted to conduct follow up appointments with Robert at least every six months. Id.

Due to continued seizure episodes, a neurologist, Dr. Alexandra E.

McBride examined Robert on May 15, 2012. Id. at 47. At that time, Robert’s medications included Keppra, Valium, and Clonazepam. The report noted that Robert had “no medication allergies.” Id. Records from that examination described Robert’s overall health as “No headaches. No visual complaints. No gait disturbance. No cardiac, pulmonary, GI, GU, dermatologic, hematologic, endocrine complaints.” Id.

On July 27, 2012, Dr. Barsh examined Robert again for his 18-year-

old physical. Pet.’s Ex. 1 at 54. Robert’s medications at that time included Valium, Keppra, Depakote, and Klonopin. Id. Robert weighed 213.5 pounds, measured 68 inches tall, his blood pressure was 130/80, and his pulse was 80. Id. Dr. Barsh noted that Robert was a healthy 18-year-old with pervasive delays and epilepsy but “doing much better on his medications at this time.” Id. Robert’s cardiac exam revealed a “regular rate and rhythm without murmur, rub or gallop.” Id. The report also mentioned that Robert attended the special education program at Fox Lane High School, worked on the computer, had decent sleep, and regular meals. Id. Mr. Yates was asked to talk with Robert’s school about incorporating an hour of physical activity into Robert’s daily routine. Id.

During the exam, blood work was ordered and a sample taken. One of the panels performed was as Complete Blood Count (“CBC”), which produces total cell counts in the blood sample, such as red blood cells and white blood cells. As will become apparent later, the relevant marker examined was Robert’s eosinophil count, a type of white blood cell, which came back as a “9.4 %.” Id. at 65.

Free access — add to your briefcase to read the full text and ask questions with AI

Yates v. Secretary of Health and Human Services, (uscfc 2020).

Yates v. Secretary of Health and Human Services (Yates v. Secretary of Health and Human Services) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related